GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
K

Kaken Pharmaceutical Co 4521.T · JPY

Health Care · Tokyo Stock Exchange · 🇯🇵 Japan

Compare

3,800

+1.60%

Close of 9 Nov 2026, in JPY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in JPY, from our data supplier.

FY2026

Revenue

¥76.87bn

FY2017FY2026

Net income

¥2.14bn

FY2017FY2026

Free cash flow

−¥14.07bn

FY2017FY2026

Shareholders' equity

¥147.62bn

FY2017FY2026

Income statement

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue¥76.87bn¥94.03bn¥72.04bn¥72.98bn¥76.03bn¥74.98bn¥89.23bn¥94.17bn¥98.43bn¥101.99bn
Gross profit¥39.24bn¥58.26bn¥38.54bn¥39.56bn¥41.58bn¥40.91bn¥50.48bn¥53.80bn¥56.03bn¥57.45bn
Research and development¥20.59bn¥18.73bn¥12.54bn¥15.79bn¥8.42bn¥6.74bn¥6.42bn¥10.26bn¥8.15bn¥6.45bn
Operating income−¥899.0m¥21.04bn¥9.52bn¥8.00bn¥17.06bn¥17.80bn¥26.52bn¥24.59bn¥27.51bn¥30.71bn
Net income¥2.14bn¥13.95bn¥8.03bn¥5.44bn¥9.55bn¥13.40bn¥19.37bn¥17.77bn¥19.04bn¥22.02bn
Diluted earnings per share56.62368.25211.89143.65254.82337.16505.64456.74472.67539.22

Balance sheet

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Total assets¥178.22bn¥190.42bn¥171.62bn¥166.33bn¥165.18bn¥165.62bn¥159.37bn¥158.11bn¥154.98bn¥135.06bn
Cash and short-term investments¥50.70bn¥70.08bn¥65.32bn¥74.26bn¥74.62bn¥77.31bn¥73.32bn¥58.55bn¥52.69bn¥43.77bn
Total liabilities¥30.59bn¥37.78bn¥27.87bn¥29.49bn¥26.85bn¥29.36bn¥30.90bn¥36.97bn¥41.10bn¥32.40bn
Debt¥3.85bn¥3.85bn¥3.85bn¥3.85bn¥3.85bn¥3.85bn¥3.85bn¥3.88bn¥3.88bn¥3.88bn
Shareholders' equity¥147.62bn¥152.63bn¥143.75bn¥136.26bn¥137.75bn¥136.26bn¥128.47bn¥121.13bn¥113.87bn¥102.66bn
Shares outstanding38m38m38m38m37m40m38m39m40m41m

Cash flow

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations−¥11.08bn¥29.78bn¥2.58bn¥9.25bn¥13.34bn¥14.38bn¥27.47bn¥21.13bn¥21.70bn¥15.33bn
Capital spending−¥3.00bn−¥4.14bn−¥1.86bn−¥2.21bn−¥3.26bn−¥2.29bn−¥2.20bn−¥1.91bn−¥1.69bn−¥2.17bn
Free cash flow−¥14.07bn¥25.64bn¥716.0m¥7.05bn¥10.08bn¥12.09bn¥25.27bn¥19.22bn¥20.01bn¥13.16bn
Dividends paid−¥6.50bn−¥7.20bn−¥5.66bn−¥5.65bn−¥5.71bn−¥5.81bn−¥5.90bn−¥6.00bn−¥6.08bn−¥6.29bn

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue¥30.15bn¥19.25bn¥18.26bn¥20.49bn¥18.87bn¥18.05bn¥24.62bn¥33.12bn
Gross profit¥20.97bn¥9.16bn¥9.25bn¥11.71bn¥9.87bn¥9.07bn¥15.09bn¥24.05bn
Operating income¥10.90bn−¥1.45bn¥352.0m¥189.0m¥14.0m−¥4.66bn¥5.84bn¥16.83bn
Net income¥8.44bn¥746.0m¥406.0m¥721.0m¥271.0m−¥5.23bn¥4.89bn¥12.53bn
Diluted earnings per share222.8519.7010.7219.047.16-138.11129.09330.89
Total assets¥187.41bn¥178.22bn¥176.44bn¥177.28bn¥176.34bn¥190.42bn¥193.42bn¥187.12bn
Cash and short-term investments¥58.14bn¥50.70bn¥45.84bn¥57.10bn¥55.40bn¥70.08bn¥79.75bn¥83.99bn
Debt¥3.85bn¥3.85bn¥3.85bn¥3.85bn¥3.85bn¥3.85bn¥3.85bn¥3.85bn
Shareholders' equity¥152.88bn¥147.62bn¥145.81bn¥147.80bn¥147.45bn¥152.63bn¥155.26bn¥154.41bn

Growth per year

Compound annual rate

3 years5 years10 years
Revenue1.7%0.5%-3.5%
Net income-26.7%-30.7%-20.5%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin57.1%55.6%55.3%56.0%
Operating margin11.8%11.9%15.5%22.6%
Net margin9.4%9.4%11.2%15.8%

Valuation history

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Price to earnings68.710.921.323.415.312.57.913.210.310.8
Price to sales1.91.62.41.71.92.21.72.52.02.3

Dividends and splits

Per share, in the currency the company pays

Paid for 36 years. Last went ex-dividend on 29 Sept 2026.

FY2027FY2026FY2025FY2024FY2023FY2022FY2021FY2020
Paid in the year95.00265.00150.00150.00150.00150.00150.00150.00
  • 2-to-1 reverse split · 28 Sept 2015
  • 1.05-for-1 split · 26 Mar 1993

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.